Equities

Nexalin Technology Inc

NXL:NAQ

Nexalin Technology Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.6942
  • Today's Change-0.006 / -0.90%
  • Shares traded132.25k
  • 1 Year change+58.13%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Nexalin Technology Inc's revenues fell -91.62% from 1.32m to 110.75k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 1.70m to a larger loss of 4.65m.
Gross margin82.94%
Net profit margin-3,598.50%
Operating margin-3,859.71%
Return on assets-160.37%
Return on equity-202.23%
Return on investment-202.23%
More ▼

Cash flow in USDView more

In 2023, Nexalin Technology Inc increased its cash reserves by 256.54%, or 417.49k. Cash Flow from Investing totalled 4.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 3.84m for operations while cash used for financing totalled 200.00k.
Cash flow per share-0.7244
Price/Cash flow per share--
Book value per share0.1781
Tangible book value per share0.1483
More ▼

Balance sheet in USDView more

Nexalin Technology Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 580.23k.
Current ratio5.57
Quick ratio4.89
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.